clinical-trials

I have read the medicinal chemistry paper and the pharmacology paper, which helped and did not finish the job. I am trying to choose between two options that are…

Details up front: a GLP-1 receptor agonist · 40 °C. I am asking for verification rather than opinion, ideally with something I can read myself. It is possible the…

I have three data points across nine months, which I hope is enough to see a trend. This is presented as though it settles something, and I am not convinced it does.…

I am asking about the protocol logic rather than about my own case specifically. This is presented as though it settles something, and I am not convinced it does. I…

Every comparison I find is either a marketing graphic putting -20.9% next to -14.9% with no caveats, or a methodology piece telling me cross-trial comparison is…

What I have: SUSTAIN-6 · early satiety · 1 mg. I can parse the result. I am less sure what it licenses me to conclude. I have deliberately not looked at anyone else’s…

I am asking about the pattern rather than about my own management, which is elsewhere. I can parse the result. I am less sure what it licenses me to conclude. I have…

Concretely: early satiety · semaglutide · STEP 1. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a…

My records go back to the first dose with dates, so I can reconstruct the timeline exactly. I would like to know the limits of what can be inferred from this. What I…

The specifics, since they change the answer: 2.4 mg · semaglutide. I would like to define my thresholds before I have a result, for obvious reasons. I want a plan…

Numbers first: STEP 2 · 2.4 mg. This is presented as though it settles something, and I am not convinced it does. I have two documents that appear to disagree, which…

For reference: fatigue · cagrilintide · REDEFINE-1. I want to understand what this actually establishes, as opposed to what it is being used to imply. My concern is…

This is a question about interpretation, not about whether to act — I will take action questions elsewhere. I want the working, not the result — I need to be able to…

The case in front of me: REDEFINE-1 · cagrilintide. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the…

Conditions: ATTAIN-1 · dizziness. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics change…

The case in front of me: nausea · tirzepatide · SURMOUNT-1. The figures are clear enough; the question is what they mean and what they do not. I can supply the…

The case in front of me: headache · tirzepatide · SURPASS-2. The figures are clear enough; the question is what they mean and what they do not. I can supply the…

What I have: SELECT · injection-site erythema. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single…

Concretely: REDEFINE-1 · vomiting · 2.4 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single…

The label documentation for the agent in question is ambiguous on exactly this point. The figures are clear enough; the question is what they mean and what they do…

Conditions: SURMOUNT-4 · 5 mg. The figures are clear enough; the question is what they mean and what they do not. I can supply the numbers if the specifics change the…

Concretely: orforglipron · room temperature. This has the shape of a fact but I cannot find its origin. What I found instead were three secondary sources all citing…

The case in front of me: PIONEER-4 · 7 mg. I would like to know the limits of what can be inferred from this. What I am trying to avoid is over-reading a single…

The case in front of me: nausea · tirzepatide · SURMOUNT-2. The figures are clear enough; the question is what they mean and what they do not. I can supply the…